VALARY LAB PRIVATE LIMITED

Overview

VALARY LAB PRIVATE LIMITED is an active pharmaceutical ingredient (API) supplier with 17 active FDA Type II Drug Master Files, covering BELZUTIFAN; BINIMETINIB; CABOZANTINIB MALATE (FORM-N2); DABRAFENIB MESYLATE; DESOGESTREL; ENCORAFENIB.

API / Drug Master Files

VALARY LAB PRIVATE LIMITED holds 17 active (17 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• DABRAFENIB MESYLATEActive2026-01-22
• DESOGESTRELActive2025-12-12
• RUXOLITINIB PHOSPHATEActive2025-07-25
• LEVONORGESTRELActive2025-07-18
• ENCORAFENIBActive2025-06-13
• BELZUTIFANActive2025-03-26
• RIBOCICLIB SUCCINATEActive2025-03-14
• ETHINYL ESTRADIOLActive2025-02-25
• CABOZANTINIB MALATE (FORM-N2)Active2025-01-03
• TIVOZANIB HYDROCHLORIDE MONOHYDRATEActive2024-12-12
• BINIMETINIBActive2024-11-27
• TRAMETINIB DIMETHYL SULFOXIDEActive2024-08-23
• PRALSETINIBActive2024-04-15
• NIRAPARIB TOSYLATE MONOHYDRATEActive2024-02-05
• LENALIDOMIDE HEMIHYDRATE (FORM-B)Active2023-09-29

Showing 15 of 17 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to VALARY LAB PRIVATE LIMITED in our records. PharmaTek screens the full directory against live FDA enforcement data.